The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
The effects of osteoprotegerin on the mechanical properties of rat bone.
Abstract
Osteoprotegerin (OPG) is a naturally secreted protein that decreases bone resorption by inhibiting osteoclast differentiation and activation while promoting osteoclast apoptosis [8]. In this study, the effects of osteoprotegerin injections on long bone mechanical and material properties were investigated in young male Sprague-Dawley rats. OPG increased fracture strength at the femur mid-diaphysis in three-point bending by 30%, without affecting the elastic or maximum strength. At the femoral neck, OPG significantly increased the elastic (45%), maximum (15%), and fracture (35%) strengths. There was not a difference in microhardness at the femur mid-diaphysis in comparing the placebo and OPG groups. There were, however, significant increases in whole bone dry mass (25%), mineral mass (30%), organic mass (17%), and percent mineralization (4%); percent mineralization at the mid-diaphysis (3%); and percent mineralization at the distal epiphysis (6%) due to the OPG treatment. While OPG decreased endocortical bone formation (52%), total bone area, endocortical bone area, and periosteal bone formation were maintained with OPG treatment. A 30% increase in the X-ray opacity of the bone at the proximal metaphysis of the right tibiae was observed. Overall, OPG increased mineralization and strength indices in the rat femur. Its effects on strength were more pronounced in the femoral neck than at the mid-diaphysis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
OPG had no influence on longitudinal bone growth in normal young rats, mice, piglets, or cynomolgus monkeys.
“OPG had no influence on longitudinal bone growth in normal young rats (185), mice (186), piglets (187), or cynomolgus monkeys (25).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [185]
OPG treatment of normal rats increases matrix mineralization and improves bone strength.
“OPG treatment of normal rats was shown to increase matrix mineralization and improve bone strength (185).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [185]
Citations
Cites
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.
Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81569-x · Cited by 5,439
Self-citationPARFITT, A. M., Drezner, M. K., Glorieux, F. H., Kanis, J. А., Malluche, H. H., Meunier, P. J., Ott, S. M., & Recker, R. R. (1987) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650020617 · Cited by 5,344
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130
Self-citationYasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S.-I., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.7.3597 · Cited by 4,224
Basic biomechanical measurements of bone: A tutorial
Turner, C. H., & Burr, D. B. (1993) · Bone · doi:10.1016/8756-3282(93)90081-k · Cited by 1,666
Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin.
Mizuno, A., Amizuka, N., Irie, K., Murakami, A., Fujise, N., Kanno, T., Sato, Y., Nakagawa, N., Yasuda, H., Mochizuki, S.-I., et al. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.8697 · Cited by 775
Morony, S., Capparelli, C., Lee, R., Shimamoto, G., Boone, T., Lacey, D. L., & Dunstan, C. R. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.9.1478 · Cited by 187
Self-citationHardness, Young's modulus and yield stress in mammalian mineralized tissues
Currey, J. D., & Brear, K. (1990) · Journal of Materials Science Materials in Medicine · doi:10.1007/bf00705348 · Cited by 150
Effects of Rehydration State on the Flexural Properties of Whole Mouse Long Bones
Broz, J. J., Simske, S. J., Greenberg, A. R., & Luttges, M. W. (1993) · Journal of Biomechanical Engineering · doi:10.1115/1.2895510 · Cited by 84
Self-citationOsteoprotegerin mitigates tail suspension-induced osteopenia.
Bateman, T. A., Dunstan, C. R., Ferguson, V. L., Lacey, D. L., Ayers, R. A., & Simske, S. J. (2000) · Bone · doi:10.1016/s8756-3282(00)00256-8 · Cited by 66
Self-citationYamamoto, M., Murakami, T., Nishikawa, M., Tsuda, E., Mochizuki, S.-I., Higashio, K., Akatsu, T., Motoyoshi, K., & Nagata, N. (1998) · Endocrinology · doi:10.1210/endo.139.9.6290 · Cited by 65
Effect of suspension on mouse bone microhardness
Simske, S. J., Broz, J. J., & Luttges, M. W. (1995) · Journal of Materials Science Materials in Medicine · doi:10.1007/bf00123375 · Cited by 9
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Kearns, A. E., Khosla, S., & Kostenuik, P. J. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0014 · Cited by 824
Self-citationKostenuik, P. J., Nguyen, H. Q., McCabe, J. G., Warmington, K. S., Kurahara, C., Sun, N., Chen, C., Li, L. Z., Cattley, R., Van, G. Y., et al. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.081112 · Cited by 448
Self-citationEffects of Denosumab on Bone Mineral Density and Bone Turnover in Postmenopausal Women
Bone, H. G., Bolognese, M. A., Yuen, C. K., Kendler, D. L., Wang, H., Liu, Y., & Martín, J. S. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2814 · Cited by 429
Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength.
KOSTENUIK, P. (2005) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.06.005 · Cited by 281
Self-citationOminsky, M. S., Li, X., Asuncion, F., Barrero, M., Warmington, K. S., Dwyer, D., Stolina, M., Geng, Z., Grisanti, M. S., Tan, H., et al. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.080109 · Cited by 132
Self-citationDelmas, P. D. (2008) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2008.02.002 · Cited by 117
Fizazi, K. S., Bosserman, L. D., Gao, G., Skácel, T., & Markus, R. A. (2012) · The Journal of Urology · doi:10.1016/j.juro.2012.11.022 · Cited by 110
Capparelli, C., Morony, S., Warmington, K., Adamu, S., Lacey, D., Dunstan, C. R., Stouch, B., Martin, S., & Kostenuik, P. J. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.5.852 · Cited by 103
Self-citationDempster, D. W., Brown, J. P., Fahrleitner‐Pammer, A., Kendler, D. L., Rizzo, S., Valter, I., Wagman, R. B., Yin, X., Yue, S. V., & Boivin, G. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-02669 · Cited by 97
Fizazi, K. S., Bosserman, L. D., Gao, G., Skácel, T., & Markus, R. A. (2009) · The Journal of Urology · doi:10.1016/j.juro.2009.04.023 · Cited by 95
Li, X., Ominsky, M. S., Stolina, M., Warmington, K. S., Geng, Z., Niu, Q., Asuncion, F., Tan, H., Grisanti, M. S., Dwyer, D., et al. (2009) · Bone · doi:10.1016/j.bone.2009.06.011 · Cited by 68
Self-citationDenosumab prevents metacarpal shaft cortical bone loss in patients with erosive rheumatoid arthritis
Sharp, J. T., Tsuji, W. H., Ory, P. A., Harper-Barek, C., Wang, H., & Newmark, R. (2010) · Arthritis Care & Research · doi:10.1002/acr.20172 · Cited by 65
RANK ligand inhibition with denosumab for the management of osteoporosis
Lewiecki, E. M. (2006) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.6.10.1041 · Cited by 58
Ominsky, M. S., Kostenuik, P. J., Cranmer, P., Smith, S. Y., & Atkinson, J. E. (2007) · Osteoporosis International · doi:10.1007/s00198-007-0363-7 · Cited by 51
Self-citationSamelson, E. J., Broe, K. E., Demissie, S., Beck, T., Karasik, D., Kathiresan, S., & Kiel, D. P. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2492 · Cited by 47
Ominsky, M. S., Stolina, M., Li, X., Corbin, T. J., Asuncion, F., Barrero, M., Niu, Q., Dwyer, D., Adamu, S., Warmington, K. S., et al. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090215 · Cited by 43
Self-citationSafety and tolerability of denosumab for the treatment of postmenopausal osteoporosis
Lewiecki, E. M. (2011) · Drug Healthcare and Patient Safety · doi:10.2147/dhps.s7727 · Cited by 42
Clinical utility of denosumab for treatment of bone loss in men and women
Adler, R. A., & Gill, R. S. (2011) · Clinical Interventions in Aging · doi:10.2147/cia.s14565 · Cited by 36
Denosumab: recent update in postmenopausal osteoporosis.
da Silva, I. S., & Branco, J. (2012) · PubMed · Cited by 33
Denosumab: an investigational drug for the management of postmenopausal osteoporosis
Lewiecki, M. E. (2008) · Biologics · doi:10.2147/btt.s2082 · Cited by 31
Skeletal deterioration induced by RANKL infusion: a model for high-turnover bone disease
Yuan, Y. Y., Kostenuik, P. J., Ominsky, M. S., Morony, S., Adamu, S., Simionescu, D. T., Basalyga, D. M., Asuncion, F., & Bateman, T. A. (2007) · Osteoporosis International · doi:10.1007/s00198-007-0509-7 · Cited by 32
Self-citationSzulc, P., Hawa, G., Boutroy, S., Vilayphiou, N., Schoppet, M., Chapurlat, R. D., & Hofbauer, L. C. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2617 · Cited by 25
Appropriate models for novel osteoporosis drug discovery and future perspectives
Gennari, L., Rotatori, S., Bianciardi, S., Gonnelli, S., Nuti, R., & Merlotti, D. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1080685 · Cited by 23
Authentication of Oviductus Ranae and Its Original Animals Using Molecular Marker.
Xuegan, Y., Yi-quan, W., Kaiya, Z., & Zhong-quan, L. (2002) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.25.1035 · Cited by 15
Denosumab: A Promising Drug for the Prevention and Treatment of Osteoporosis
Lewiecki, E. M. (2006) · Women s Health · doi:10.2217/17455057.2.4.517 · Cited by 12
Bonnet, N., Gerbaix, M., Ominsky, M. S., Ammann, P., Kostenuik, P. J., & Ferrari, S. (2016) · Calcified Tissue International · doi:10.1007/s00223-016-0124-8 · Cited by 9
Self-citationGaraicoa‐Pazmiño, C., Decker, A. M., & Polverini, P. J. (2015) · Springer eBooks · doi:10.1007/978-3-319-23297-3_8 · Cited by 8
Antibodies for the Treatment of Bone Diseases: Preclinical Data
Sipos, W. (2016) · Springer eBooks · doi:10.1007/978-3-319-34238-2_9 · Cited by 4
Der RANK-Ligand-Antikörper Denosumab als Beispiel der biotechnologischen Medikamentenentwicklung
Trubrich, A., Kocijan, R., Muschitz, C., & Resch, H. (2011) · Osteologie/Osteology · doi:10.1055/s-0037-1619994 · Cited by 3
RANK/RANK-Ligand/OPG: Ein neuer Therapieansatz in der Osteoporosebehandlung
Preisinger, E. (2007) · Journal für Kardiologie (Krause & Pachernegg GmbH) · Cited by 3
Payne, K. A., Shaw, N. M., Erickson, C. B., Yarger, P., Yu, Y., Baldini, T. H., Kleck, C. J., Patel, V. V., & Burger, E. L. (2022) · Spine · doi:10.1097/brs.0000000000004412 · Cited by 2
RANKL Inhibition: Preclinical Data
Sipos, W. (2011) · Springer eBooks · doi:10.1007/978-3-7091-0520-7_9 · Cited by 1
The differential effects of two critical osteoclastogenesis stimulating factors on bone biomechanics
Yuan, Y. (2007) · TigerPrints (Clemson University) · Cited by 1
Osteoporosis Therapy: Mechanistic Antiresorptives
Dodge, J. A., & Bryant, H. U. (2010) · Wiley eBooks · doi:10.1002/0471266949.bmc197
Osteoporosis and sarcopenia in older adults
Chalhoub, D. (2015) · D-Scholarship@Pitt (University of Pittsburgh)
Kendler, D. L. (2010) · Orthopedic Research and Reviews · doi:10.2147/orr.s6124
A pharmacodynamic investigation into the efficacy of osteoprotegerin during aseptic inflammation
Curl, L., Barker, C., Dreyer, C. W., & Sampson, W. J. (2012) · Australasian Orthodontic Journal · doi:10.2478/aoj-2012-0020
Osteoporosis Therapy: Mechanistic Antiresorptives
Dodge, J. A., & Bryant, H. U. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc197.pub2
Echtler, S. (2014) · Electronic Theses of LMU Munich (Ludwig-Maximilians-Universität München) · doi:10.5282/edoc.17260
Metadata
- Authors
- Ross, A. B., Bateman, T. A., Kostenuik, P. J., Ferguson, V. L., Lacey, D. L., Dunstan, C. R., & Simske, S. J.
- Affiliations
- University of Colorado Boulder (US)
- Amgen (United States) (US)
- Corresponding author
- Bateman, Ted A.
- Venue
- Journal of Materials Science: Materials in Medicine
- Published
- 2001-07
- Volume
- 12
- Issue
- 7
- Pages
- 583-588
- ISSN
- 0957-4530 (ISSN-L)
- 1573-4838
- OpenAlex
- W194340635
- Cited by
- 39
- References
- 12
- Citations by year
- 2022: 1 · 2021: 1 · 2018: 1 · 2016: 2 · 2015: 3 · 2014: 1 · 2012: 3
- FWCI
- 0.23
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Journal of Materials Science Materials in Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Aeronautics and Space Administration
- Amgen
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Physical Sciences › Engineering › Biomedical Engineering › Bone Tissue Engineering Materials
- Keywords
- osteoprotegerin, bone mechanical properties, bone mineralization, bone strength, femoral neck, femoral diaphysis, bone mineral mass, bone formation, bone resorption, three-point bending, microhardness, X-ray opacity, rat femur
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
